Novartis AG To Spin-Off Sandoz Business In 4Q23

Deal Overview On July 18, 2023, Novartis AG (NYSE: NVS, $105.01, Market Capitalization $239.2 billion), a leading global medicine company, announced that its Board of ...

Related Keywords

United States ,Ljubljana ,Slovenia General ,Slovenia ,Holzkirchen ,Bayern ,Germany ,Delaware ,San Diego ,California ,Lendava ,Lendava Lendva ,Switzerland ,Swiss ,American ,Novartis Remainco ,Evotec Biologics ,Gilbert Ghostine ,Richard Saynor ,Us District Court ,Evotec Biologics Partnership ,Biosimilar Technical Development Center ,Sandoz Biopharma Development Center ,Novartis ,Swiss Exchange ,Company Description ,Alnylam Pharmaceuticals ,Dtx Pharma Inc ,Us Court ,Market Capitalization ,American Depositary Receipt ,Extraordinary General Meeting ,Shareholder Brochure ,Innovative Medicines ,Novartis Campus ,Chief Executive Officer ,Vas Narasimhan ,Novartis Innovative ,Federal Circuit ,Pharma Inc ,Chinook Therapeutics ,Just Evotec Biologics Partnership ,Just Evotec Biologics ,Novartis Ag To Spin Off Sandoz Business ,Novartis Ag ,Sandoz ,Us ,Spin Off Research ,Spin Off ,